Clinical Trial Update: Targeted Survivin DC Cell Injection for the Treatment of GBM [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of a targeted survivin dendritic cell injection for glioblastoma. The study is sponsored by Beijing Tricision Biotherapeutics Inc and is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Targeted Survivin DC Cell Injection

Snippet

Sponsor: Beijing Tricision Biotherapeutics Inc | Conditions: Glioblastoma | Phase 1 | Status: NOT_YET_RECRUITING